GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Subscribe To Our Newsletter & Stay Updated
